Safety, Tolerability, and Pharmacokinetics of Belumosudil, a Selective Rho-associated Coiled-coil-containing Protein Kinase 2 Inhibitor, in Healthy Japanese Volunteers: A PhaseⅠ, Randomized, Controlled Trial-Reference-Cited by-同舟云学术

Safety, Tolerability, and Pharmacokinetics of Belumosudil, a Selective Rho-associated Coiled-coil-containing Protein Kinase 2 Inhibitor, in Healthy Japanese Volunteers: A PhaseⅠ, Randomized, Controlled Trial

Published:2023-09-30 Issue:5 Volume:54 Page:197-203
ISSN:0388-1601
Container-title:Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:Jpn. J. Clin. Pharmacol. Ther.

Author:

OGAMA Yoichiro¹,SATO Hiroki²,MIYATA Atsunori³,KIJIMA Koji²,KUMAGAI Yuji⁴

Affiliation:

1. Sumida Hospital, SOUSEIKAI, Tokyo, Japan

2. Clinical Development Dept., R&D Division, Meiji Seika Pharma Co., Ltd, Tokyo, Japan

3. Drug Discovery Dept., R&D Division, Meiji Seika Pharma Co., Ltd, Tokyo, Japan

4. Kitasato Clinical Research Center, Kitasato University School of Medicine, Kanagawa, Japan

Publisher

Japanese Society of Clinical Pharmacology and Therapeutics

Subject

Pharmacology (medical),Pharmacology

Link

https://www.jstage.jst.go.jp/article/jscpt/54/5/54_197/_pdf

Reference21 articles.

1. 1) Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22（3）: 449-55. doi: 10.1016/j.bbmt.2015.10.018.

2. 2) Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29（16）: 2230-9. doi: 10.1200/JCO.2010.33.7212.

3. 3) The Japanese Data Center for Hematopoietic Cell Transplantation, The Japanese Society for Transplantation and Cellular Therapy. Hematopoietic cell transplantation in Japan: Annual report of nationwide survey 2021. ［http://www.jdchct.or.jp/data/report/2021（accessed 2023-04-30）］（in Japanese）

4. 4) Inamoto Y, Matsuoka K. JSHCT meeting symposium report: current status and future perspective of chronic graft-versus-host disease. J Hematopoietic Cell Transplantation. 2018; 7 (2）: 56-63. doi: 10.7889/hct-17-016. （in Japanese）

5. 5) The Japanese Society for Transplantation and Cellular Therapy. Guidelines for hematopoietic cell transplantation-GVHD. 5th ed. ［https://www.jstct.or.jp/modules/guideline/index.php?content_id=1 (accessed 2023-04-30）］（in Japanese）

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD;American Journal of Hematology;2024-06-27